Slow release injectable materials

We have developed injectable materials that are ideal for slow release of highly potent drugs and proteins used in the treatment of serious conditions such as cancer.

The Challenge

Safe drug delivery

The medical research community is continually seeking effective forms of disease fighting drugs, while minimising side effects for patients.

Standard treatments for conditions such as cancer use potent drugs that are administered via intravenous methods, rather than localised delivery. This form of treatment can inadvertently cause serious side effects, in some case as severe as organ failure.

Other treatments require a higher frequency of therapeutic delivery due to rapid clearance from the site of treatment.

Our Response

Slow release drug deposits

We have been investigating the physical and mechanical characteristics of our thermo-responsive polymers (TRPs).

Dr Tash Polyzos and Mr Martin Brzozowski in the Flow Chemistry lab.

We are optimising formulations for use in a range of applications together with respective drug therapies. We've had positive results for the combination of certain cancer drugs (Doxorubicin and Dipyridamole) with our slow release polymer technology.

The formulations have a liquid consistency at room temperature. Injected with a 25 gauge needle, they gel instantaneously at body temperature encapsulating the therapeutic dose for slow release.

We are now studying other potent drug treatments with varying molecular weights and comparing them to existing technologies.

The Results

Tailored drug therapies

Our materials allow the localised delivery and slow release of therapeutic molecules at significantly lower doses, releasing the drug over a tailored period of time. This offers potentially reduced side effects and no damage to other organs.

Compared to similar technologies currently under clinical evaluation, our materials have been proven to release over a significantly longer period of time, minimising the frequency of intervention over the period of treatment. The formulations have been shown to be stable for over two years.

This technology has the potential to:

  • Administer precise localised placement of potent drugs
  • Control slow release drug therapies minimising the frequency of clinical visits
  • Lower doses, preventing serious side effects
  • Ease delivery of injection
  • Significantly reduce trauma to patients.


Have an enquiry about this page?

Contact us

Do business with us to help your organisation thrive

We partner with small and large companies, government and industry in Australia and around the world.

Contact us now to start doing business